Share

CASI Pharmaceuticals Inc. - news published 79 - readings 1.277

BACK
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 20-F)

OPERATING AND FINANCIAL REVIEW AND PROSPECTS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this annual report on Form 20-F. This discussion may contain forward-looking statements based upon current expectations that ...

Continue reading
31.03.2025
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 BUSINESS AND FINANCIAL RESULTS (Form 6-K)

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 BUSINESS AND FINANCIAL RESULTS BEIJING, China (March 31, 2025) CASI Pharmaceuticals, Inc. (Nasdaq: CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results f ...

Continue reading
31.03.2025
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the fourth quarter ended December 31, 2024, a ...

Continue reading
31.03.2025
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Received Interim Relief in connection with the Dispute with Juventas (Form 6-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 Ji ...

Continue reading
10.02.2025
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Receives Asset Freezing Order from Court of P.R. China (Form 6-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 Jia ...

Continue reading
21.01.2025
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Clinical Hold of CID 103 for Antibody Mediated Rejection (AMR) of Kidney Transplant Form 6 K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 Ji ...

Continue reading
26.12.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

Amendment to Registration Statement by Foreign Issuer Specific Transactions (Form F 3/A)

As filed with the Securities and Exchange Commission on December 23, 2024 Registration No. 333-283998 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No. 1 To FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CASI Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands Not Applic ...

Continue reading
23.12.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

Registration Statement by Foreign Issuer Specific Transactions (Form F 3)

As filed with the Securities and Exchange Commission on December 20, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CASI Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands Not Applicable (State or other jurisdiction of in ...

Continue reading
20.12.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Received Termination Process Letter for License of Evomela® from Acrotech Form 6 K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 Ji ...

Continue reading
16.12.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2024 BUSINESS AND FINANCIAL RESULTS Form 6 K

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2024 BUSINESS AND FINANCIAL RESULTS BEIJING, China (November 15, 2024) CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported b ...

Continue reading
15.11.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

BEIJING, CHINA, October 24, 2024 -CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (C ...

Continue reading
25.10.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Change of Senior Management Positions Form 6 K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 001-41666 CASI PHARMACEUTICALS, INC. (Translation of registrant's name into English) 1701-1702, China Central Office Tower 1 No. 81 J ...

Continue reading
12.09.2024
CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Second Quarter 2023 Business and Financial Updates

BEIJING, China (August 11, 2023) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the quarter ended June 30, 2023. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $9.8 ...

Continue reading
14.08.2023